Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Efficacy Study of Aclasta on Prosthetic Fixation in Postmenopausal Women After THA
NCT02333344 · Novartis Pharmaceuticals · PHASE4 · withdrawn · last registry update 2019-09-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study halted prematurely, prior to enrollment of first participant, for strategic reasons” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FDPS within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-08-21Also stopped (terminated): Johns Hopkins University, Teriparatide + Alendronate (NCT01656629)
- 2020-07-17Results posted on the registry: Massachusetts General Hospital, rhIGF-1 + Risedronate (NCT01406444)
- 2020-05-12Results posted on the registry: University of California, San Francisco, Zoledronic Acid (NCT00295867)
- 2020-04-28Results posted on the registry: City of Hope Medical Center, zoledronic acid (NCT01409811)
- 2020-03-24Results posted on the registry: Gynecologic Oncology Group, Zoledronic Acid (NCT00305695)
- 2020-03-18Also stopped (terminated): Stanford University, zoledronic acid (NCT00226954)
- 2020-03-10Phase 3 first posted: Vestre Viken Hospital Trust, Zoledronic Acid + Saline 0.9% (NCT04303026)
- 2019-12-12Also stopped (terminated): Hamad Medical Corporation, Denosumab 60 MG/ML Prefilled Syringe + Zoledronic Acid 5Mg/Bag 100Ml Inj (NCT03040765)
- 2019-11-25Also stopped (terminated): University of Wisconsin, Madison, IL2 + Zoledronic acid (NCT00582790)
- 2019-11-20Phase 3 first posted: Ain Shams University, Denosumab 60 mg/ml [Prolia] + Alendronate 70Mg Tab (NCT04169698)
- 2019-11-18Results posted on the registry: University of Louisville, Simvastatin and zoledronic acid (NCT01772719)
- 2019-11-18Also stopped (terminated): University of Louisville, Simvastatin and zoledronic acid (NCT01772719)
- 2019-09-20Results posted on the registry: Novartis Pharmaceuticals, Zoledronic acid (NCT01197300)
- 2019-09-13Also stopped (terminated): Oslo University Hospital, Zoledronic Acid Injectable Product + Placebo (NCT03576599)
- 2019-08-28Results posted on the registry: SWOG Cancer Research Network, clodronate disodium + ibandronate sodium (NCT00127205)
- 2019-08-08Results posted on the registry: Johns Hopkins University, Teriparatide + Alendronate (NCT01656629)
- 2019-08-05Results posted on the registry: Hanlim Pharm. Co., Ltd., Risedronate/Cholecalciferol combination + Risedronate (NCT01675297)
- 2019-07-26Phase 3 first posted: Kwong Wah Hospital, Denosumab + Zoledronic Acid (NCT04034199)
- 2019-07-05Results posted on the registry: Novartis Pharmaceuticals, Zoledronic acid + Placebo (NCT00799266)
- 2019-07-02Results posted on the registry: City of Hope Medical Center, filgrastim + recombinant interferon alfa (NCT00004088)
- 2019-05-15Phase 3 first posted: Institut Cancerologie de l'Ouest, Zoledronic Acid 4Mg Solution for Injection + Hypo-fractured radiotherapy in stereotactic conditions (NCT03951493)
- 2019-04-29Phase 3 first posted: University of Guadalajara, Colaren in HIV positive + standard treatment in HIV positive (NCT03930992)
- 2019-04-16Also stopped (terminated): Spanish Breast Cancer Research Group, Zoledronic acid (NCT00130494)
- 2019-03-13Also stopped (withdrawn): Germans Trias i Pujol Hospital, Ibandronate (NCT00662077)
- 2019-03-04Results posted on the registry: Amgen, Romosozumab (NCT01588509)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision